

Elizabeth M Kutter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3724614/publications.pdf>

Version: 2024-02-01

44
papers

6,136
citations

126901
33
h-index

315719
38
g-index

47
all docs

47
docs citations

47
times ranked

5909
citing authors

#	ARTICLE	IF	CITATIONS
1	Hydrogel formulations containing non-ionic polymers for topical delivery of bacteriophages. <i>International Journal of Pharmaceutics</i> , 2021, 605, 120850.	5.2	15
2	Current Updates from the Long-Standing Phage Research Centers in Georgia, Poland, and Russia. , 2021, , 921-951.		8
3	The genetic basis of phage susceptibility, cross-resistance and host-range in <i>Salmonella</i> . <i>Microbiology (United Kingdom)</i> , 2021, 167, .	1.8	20
4	Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	28
5	Phage Therapy. , 2020, , 777-787.e3.		4
6	Development of a broad-spectrum <i>Salmonella</i> phage cocktail containing Viunalike and Jerseylike viruses isolated from Thailand. <i>Food Microbiology</i> , 2020, 92, 103586.	4.2	31
7	Inhalable combination powder formulations of phage and ciprofloxacin for <i>P. aeruginosa</i> respiratory infections. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 142, 543-552.	4.3	48
8	Structure and Function of the Branched Receptor-Binding Complex of Bacteriophage CBA120. <i>Journal of Molecular Biology</i> , 2019, 431, 3718-3739.	4.2	67
9	Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of <i>Pseudomonas aeruginosa</i> Biofilm Isolated from Cystic Fibrosis and Wound Patients. <i>AAPS Journal</i> , 2019, 21, 49.	4.4	64
10	Jet nebulization of bacteriophages with different tail morphologies – Structural effects. <i>International Journal of Pharmaceutics</i> , 2019, 554, 322-326.	5.2	31
11	Compassionate Use of Bacteriophage Therapy for Foot Ulcer Treatment as an Effective Step for Moving Toward Clinical Trials. <i>Methods in Molecular Biology</i> , 2018, 1693, 159-170.	0.9	59
12	Bacteriophages: A Therapy Concept against Multi-Drug-Resistant Bacteria. <i>Surgical Infections</i> , 2018, 19, 737-744.	1.4	76
13	Resolving Digital Staphylococcal Osteomyelitis Using Bacteriophage – A Case Report. <i>Antibiotics</i> , 2018, 7, 87.	3.7	64
14	From Host to Phage Metabolism: Hot Tales of Phage T4's Takeover of <i>E. coli</i> . <i>Viruses</i> , 2018, 10, 387.	3.3	52
15	Microfluidic-assisted bacteriophage encapsulation into liposomes. <i>International Journal of Pharmaceutics</i> , 2018, 545, 176-182.	5.2	35
16	Current Updates from the Long-Standing Phage Research Centers in Georgia, Poland, and Russia. , 2018, , 1-31.		13
17	Production of highly stable spray dried phage formulations for treatment of <i>Pseudomonas aeruginosa</i> lung infection. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 121, 1-13.	4.3	84
18	Bacteriophage T4 Infection of Stationary Phase <i>E. coli</i> : Life after Log from a Phage Perspective. <i>Frontiers in Microbiology</i> , 2016, 7, 1391.	3.5	131

#	ARTICLE	IF	CITATIONS
19	Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections. <i>Pharmaceutical Research</i> , 2016, 33, 1486-1496.	3.5	106
20	Phage Î Pan70, a Putative Temperate Phage, Controls <i>Pseudomonas aeruginosa</i> in Planktonic, Biofilm and Burn Mouse Model Assays. <i>Viruses</i> , 2015, 7, 4602-4623.	3.3	42
21	What Can We Learn from a Metagenomic Analysis of a Georgian Bacteriophage Cocktail?. <i>Viruses</i> , 2015, 7, 6570-6589.	3.3	38
22	Quality and Safety Requirements for Sustainable Phage Therapy Products. <i>Pharmaceutical Research</i> , 2015, 32, 2173-2179.	3.5	176
23	Phage Therapy: Bacteriophages as Natural, Self-Replicating Antimicrobials. , 2015, , 883-908.		3
24	Phage Therapy. , 2013, , 191-231.		4
25	Phage Therapy. , 2013, , 945-956.		3
26	The Susceptibility of <i>Pseudomonas aeruginosa</i> Strains from Cystic Fibrosis Patients to Bacteriophages. <i>PLoS ONE</i> , 2013, 8, e60575.	2.5	73
27	A suggested new bacteriophage genus: “Viunalikevirus”. <i>Archives of Virology</i> , 2012, 157, 2035-2046.	2.1	77
28	Tackling antibiotic resistance. <i>Nature Reviews Microbiology</i> , 2011, 9, 894-896.	28.6	919
29	Evaluation of lytic activity of staphylococcal bacteriophage Sbâ€1 against freshly isolated clinical pathogens. <i>Microbial Biotechnology</i> , 2011, 4, 643-650.	4.2	134
30	Characterization of a VII-like Phage Specific to <i>Escherichia coli</i> O157:H7. <i>Virology Journal</i> , 2011, 8, 430.	3.4	60
31	Naturally resident and exogenously applied T4-like and T5-like bacteriophages can reduce<i>Escherichia coli</i>O157. <i>Bacteriophage</i> , 2011, 1, 15-24.	1.9	71
32	Phage treatment of human infections. <i>Bacteriophage</i> , 2011, 1, 66-85.	1.9	734
33	Phage Therapy in Clinical Practice: Treatment of Human Infections. <i>Current Pharmaceutical Biotechnology</i> , 2010, 11, 69-86.	1.6	550
34	Phage Host Range and Efficiency of Plating. <i>Methods in Molecular Biology</i> , 2009, 501, 141-149.	0.9	312
35	Bacteriophage Isolated from Feedlot Cattle Can Reduce<i>Escherichia coli</i>O157:H7 Populations in Ruminant Gastrointestinal Tracts. <i>Foodborne Pathogens and Disease</i> , 2008, 5, 183-191.	1.8	127
36	Isolation and Characterization of a New T-Even Bacteriophage, CEV1, and Determination of Its Potential To Reduce <i>Escherichia coli</i> O157:H7 Levels in Sheep. <i>Applied and Environmental Microbiology</i> , 2006, 72, 6405-6410.	3.1	141

#	ARTICLE	IF	CITATIONS
37	Isolation of Escherichia coli Bacteriophages from the Stool of Pediatric Diarrhea Patients in Bangladesh. Journal of Bacteriology, 2004, 186, 8287-8294.	2.2	85
38	In Vitro and In Vivo Bacteriolytic Activities of Escherichia coli Phages: Implications for Phage Therapy. Antimicrobial Agents and Chemotherapy, 2004, 48, 2558-2569.	3.2	202
39	Bacteriophage T4 Genome. Microbiology and Molecular Biology Reviews, 2003, 67, 86-156.	6.6	673
40	The Roles of the Bacteriophage T4 r Genes in Lysis Inhibition and Fine-Structure Genetics: A New Perspective. Genetics, 1998, 148, 1539-1550.	2.9	85
41	Evolution of T4-related phages. Virus Genes, 1995, 11, 285-297.	1.6	80
42	Bacteriophage T4 Alc protein: A transcription termination factor sensing local modification of DNA. Cell, 1993, 75, 147-154.	28.9	50
43	A restriction map of the bacteriophage T4 genome. Molecular Genetics and Genomics, 1980, 179, 421-435.	2.4	342
44	Degradation of cytosine-containing bacterial and bacteriophage DNA after infection of Escherichia coli B with bacteriophage T4D wild type and with mutants defective in genes 46, 47 and 56. Journal of Molecular Biology, 1968, 38, 395-411.	4.2	195